Robert G. Bristow, MD, PhD, on Prostate Cancer: Keynote Lecture
2018 Genitourinary Cancers SymposiumRobert G. Bristow, MD, PhD, of Manchester Cancer Research Centre, discusses germline and somatic mutations; new ways to generate biomarkers that may describe tumor complexity; and how, in the future, this information may help triage patients with aggressive prostate tumors to intensified treatments.
Related Videos
Daniel J. George, MD, on RCC: Study Results on Adjuvant Treatment
Daniel J. George, MD, of Duke University Medical Center, discusses phase III findings on adjuvant sunitinib in patients with high-risk renal cell carcinoma, in an exploratory pharm...
Laurence Albiges, MD, PhD, on RCC: Results From the NIVOREN GETUG-AFU 26 Trial
Laurence Albiges, MD, PhD, of the Gustave Roussy Cancer Centre, discusses study findings on the safety and efficacy of nivolumab in metastatic renal cell carcinoma (Abstract 577).<...
Thomas Powles, MD, on Urothelial Carcinoma: Results From the IMvigor211 Trial
Thomas Powles, MD, of Barts Cancer Institute, discusses phase III study findings on atezolizumab vs chemotherapy in platinum-treated locally advanced or metastatic urothelial carci...
Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial
Nicholas D. James, MBBS, PhD, of University Hospitals Birmingham NHS Foundation Trust, discusses study findings on the addition of docetaxel to first-line hormone therapy in prosta...
Gregory R. Pond, PhD, on Urothelial Cancer: Advance in Prognosis
Gregory R. Pond, PhD, of McMaster University, discusses a new six-factor prognostic model for patients with advanced urothelial carcinoma receiving post platinum atezolizumab (Abst...
